Every article, report, and earnings note where ZTS appears.
Zoetis’ 5.97% selloff looks like a concentrated U.S. pet-demand reset, not a broken animal-health franchise. At 12.39x trailing earnings and a 37.0% operating margin, ZTS offers long-term bulls a better entry than its old premium valuation did.
Zoetis remains a Buy for investors willing to wait for a premium pet-care rebound. Strong margins, cash flow, and a deep pipeline are offset by softer U.S. companion-animal trends and elevated leverage.
Seven pet care stocks ranked by investment quality, from specialty pharmacy and insurance to omnichannel retail and branded pet food.
Zoetis Inc. (ZTS) falls sharply after reporting Q1 2026 results that missed expectations and came with softer full-year guidance. The selloff reflects weaker U.S. revenue, a profit miss, and a market reset for the animal-health leader.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate ZTS ReportCancel anytime